Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2011 Brian Orelli	Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you?
The Motley Fool January 30, 2009 Brian Orelli	Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics.
The Motley Fool July 25, 2007 Ryan Fuhrmann	The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count.
The Motley Fool July 14, 2009 Brian Orelli	Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow.
The Motley Fool February 13, 2009 Brian Orelli	Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered.
The Motley Fool July 24, 2006 Ryan Fuhrmann	The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors?
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool June 15, 2005 Bobby Shethia	A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note.
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
The Motley Fool September 13, 2010 Brian Orelli	When All Else Fails, Sell! Genzyme has no other choice.
The Motley Fool October 5, 2006 Rich Smith	Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors.
The Motley Fool June 20, 2008 Brian Orelli	Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics.
The Motley Fool April 20, 2010 Jim Mueller	Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors.
The Motley Fool June 10, 2008 Brian Orelli	Third Wave's Invader Gets Invaded Hologic picks up a promising technology as the diagnostic-testing market picks up steam.
The Motley Fool April 16, 2008 Ryan Fuhrmann	MEDTOX Fails the Test The Motley Fool - MEDTOX posted a weak quarter from a tough job market.
The Motley Fool March 31, 2011 David Williamson	Embarking on a Profitable Quest Quest Diagnostics has been busy, snapping up a pair of smaller players and seeing its share price recover to near 52-week highs. Let's take a look at what these acquisitions mean going forward.
The Motley Fool October 17, 2011	Laboratory Corp. of America Holdings Earnings Preview Laboratory Corp. of America Holdings will unveil its latest earnings on Thursday, October 20, and analysts predict a rise of 10% in revenue.
The Motley Fool May 8, 2006 Tom Taulli	Quest Software: Hugging Microsoft By expanding its products to the Microsoft line, the software company should see more growth. Investors, take note.
The Motley Fool April 27, 2005 Tim Hanson	Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio.
The Motley Fool November 8, 2007 Brian Orelli	The 2 Sides of Bio-Rad Results for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales.
The Motley Fool October 24, 2006 Ryan Fuhrmann	LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings.
The Motley Fool December 15, 2008 Brian Orelli	Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it?
The Motley Fool March 29, 2011 Brian Orelli	Partnership Now, Payoff Later ARIAD signs up a partner to develop a companion diagnostic.
The Motley Fool June 11, 2007 Billy Fisher	Big Dollars in Diagnostic Deals CIGNA extends multi-year deals to a pair of powerhouses. The Quest agreement is a comfort to investors, who now know that Quest will continue to be a contracted provider for one of the nation's largest health insurers.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool October 25, 2010 Rich Smith	This Just In: Upgrades and Downgrades Standpoint Capital believes that ExxonMobil, Quest Diagnostics, and Lockheed Martin have nowhere to go but up.
Chemistry World June 9, 2015 Phillip Broadwith	Opko deepens diagnostics with $1.5bn lab buyout Healthcare firm Opko is aiming to enhance its position in diagnostic technology by agreeing to buy clinical diagnostics service BioReference Laboratories.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool July 21, 2005 W.D. Crotty	The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet.
Chemistry World October 29, 2015 Anthony King	Poor diagnostics hinder battle against antibiotic resistance The tools used to diagnose bacterial infections have barely improved since the 1940s.
The Motley Fool July 26, 2007 Ryan Fuhrmann	LabCorp Leaps Forward LabCorp continues to fire on all cylinders. Investors, take note.
Pharmaceutical Executive March 1, 2011 Jerry Coamey	Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution
The Motley Fool September 24, 2008 Brian Orelli	100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
Bio-IT World March 2007 Michael A. Greeley	Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities.
The Motley Fool February 15, 2007 Ryan Fuhrmann	LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.
The Motley Fool June 13, 2008 Brian Orelli	China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.
The Motley Fool November 30, 2010 Brian Orelli	Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers.
The Motley Fool February 8, 2007 Rich Duprey	Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool February 23, 2010 Brian Orelli	Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
Pharmaceutical Executive March 1, 2013 Keeling & Paz	Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics.
Managed Care June 2006	Excessive Use of Screening Tests Costs System Millions Each Year Managed care always couched its emphasis on prevention with the caveat that diagnostic tests should be conducted according to generally accepted national practice guidelines. A new study seems to indicate just how costly preventive medicine can be when not tied to a disciplined approach.
The Motley Fool January 23, 2007 Billy Fisher	Strong Start at Meridian Bioscience From an earnings standpoint, the Cincinnati-based life science company reported another record quarter, and it should continue to impress onlookers in the months ahead.